Screening is important for the diagnosis and treatment of a wide variety of diseases. A good screening policy should be personalized to the features of the patient and to the dynamic history of the patient (including the history of screening).

Precise prognostic stratification of colorectal cancer (CRC) remains a major clinical challenge due to its high heterogeneity. The conventional TNM staging system is inadequate for personalized medicine. We aimed to develop and validate a novel multiple instance learning model TDAM-CRC using histopathological whole-slide images for accurate prognostic prediction and to uncover its underlying molecular mechanisms. We trained the model on the TCGA discovery cohort (n=581), validated it in an independent external cohort (n=1031), and further we integrated multi-omics data to improve model interpretability and identify novel prognostic biomarkers. The results demonstrated that the TDAM-CRC achieved robust risk stratification in both cohorts. Its predictive performance significantly outperformed the conventional clinical staging system and multiple state-of-the-art models. The TDAM-CRC risk score was confirmed as an independent prognostic factor in multivariable analysis. Multi-omics analysis revealed that the high-risk subtype is closely associated with metabolic reprogramming and an immunosuppressive tumor microenvironment. Through interaction network analysis, we identified and validated Mitochondrial Ribosomal Protein L37 (MRPL37) as a key hub gene linking deep pathomic features to clinical prognosis. We found that high expression of MRPL37, driven by promoter hypomethylation, serves as an independent biomarker of favorable prognosis. Finally, we constructed a nomogram incorporating the TDAM-CRC risk score and clinical factors to provide a precise and interpretable clinical decision-making tool for CRC patients. Our AI-driven pathological model TDAM-CRC provides a robust tool for improved CRC risk stratification, reveals new molecular targets, and facilitates personalized clinical decision-making.

Accurate and interpretable survival analysis remains a core challenge in oncology. With growing multimodal data and the clinical need for transparent models to support validation and trust, this challenge increases in complexity. We propose an interpretable multimodal AI framework to automate survival analysis by integrating clinical variables and computed tomography imaging. Our MultiFIX-based framework uses deep learning to infer survival-relevant features that are further explained: imaging features are interpreted via Grad-CAM, while clinical variables are modeled as symbolic expressions through genetic programming. Risk estimation employs a transparent Cox regression, enabling stratification into groups with distinct survival outcomes. Using the open-source RADCURE dataset for head and neck cancer, MultiFIX achieves a C-index of 0.838 (prediction) and 0.826 (stratification), outperforming the clinical and academic baseline approaches and aligning with known prognostic markers. These results highlight the promise of interpretable multimodal AI for precision oncology with MultiFIX.

Type 2 Diabetes Mellitus (T2DM) remains a global health challenge, underscoring the need for early and accurate risk prediction. This study presents ECG-DiaNet, a multimodal deep learning model that integrates electrocardiogram (ECG) features with clinical risk factors (CRFs) to enhance T2DM onset prediction. Using data from Qatar Biobank (QBB), we trained and validated models on a development cohort (n=2043) and evaluated performance on a longitudinal test set (n=395) with five-year follow-up. ECG-DiaNet outperformed unimodal ECG-only and CRF-only models, achieving a higher AUROC (0.845 vs 0.8217) than the CRF-only model, with statistical significance (DeLong p<0.001). Reclassification metrics further confirmed improvements: Net Reclassification Improvement (NRI=0.0153) and Integrated Discrimination Improvement (IDI=0.0482). Risk stratification into low-, medium-, and high-risk groups showed ECG-DiaNet achieved superior positive predictive value (PPV) in high-risk individuals. The model's reliance on non-invasive and widely available ECG signals supports its feasibility in clinical and community health settings. By combining cardiac electrophysiology and systemic risk profiles, ECG-DiaNet addresses the multifactorial nature of T2DM and supports precision prevention. These findings highlight the value of multimodal AI in advancing early detection and prevention strategies for T2DM, particularly in underrepresented Middle Eastern populations.

Screening is important for the diagnosis and treatment of a wide variety of diseases. A good screening policy should be personalized to the features of the patient and to the dynamic history of the patient (including the history of screening). The growth of electronic health records data has led to the development of many models to predict the onset and progression of different diseases. However, there has been limited work to address the personalized screening for these different diseases. In this work, we develop the first framework to construct screening policies for a large class of disease models.

Gastric and oesophageal (OG) cancers are the leading causes of cancer mortality worldwide. In OG cancers, recent studies have showed that PDL1 immune checkpoint inhibitors (ICI) in combination with chemotherapy improves patient survival. However, our understanding of the tumour immune microenvironment in OG cancers remains limited. In this study, we interrogate multiplex immunofluorescence (mIF) images taken from patients with advanced Oesophagogastric Adenocarcinoma (OGA) who received first-line fluoropyrimidine and platinum-based chemotherapy in the PLATFORM trial (NCT02678182) to predict the efficacy of the treatment and to explore the biological basis of patients responding to maintenance durvalumab (PDL1 inhibitor). Our proposed Artificial Intelligence (AI) based marker successfully identified responder from non-responder (p < 0.05) as well as those who could potentially benefit from ICI with statistical significance (p < 0.05) for both progression free and overall survival. Our findings suggest that T cells that express FOXP3 seem to heavily influence the patient treatment response and survival outcome. We also observed that higher levels of CD8+PD1+ cells are consistently linked to poor prognosis for both OS and PFS, regardless of ICI.

Several artificial neural networks (ANNs) have been developed recently to predict the prognosis of different types of cancer based on the tumor transcriptome. However, they have not demonstrated significantly better performance than the regularized Cox proportional hazards regression model. Training an ANN is challenging with a limited number of data samples and a high-dimensional feature space. Recent advancements in image classification have shown that contrastive learning (CL) can facilitate further learning tasks by learning good feature representation from a limited number of data samples. In this paper, we applied supervised CL to tumor gene expression and clinical data to learn feature representations in a low-dimensional space. We then used these learned features to train a Cox model for predicting cancer prognosis. Using data from The Cancer Genome Atlas (TCGA), we demonstrated that our CL-based Cox model (CLCox) significantly outperformed existing methods in predicting the prognosis of 19 types of cancer considered. We also developed CL-based classifiers to classify tumors into different risk groups and showed that CL can significantly improve classification accuracy. Specifically, our CL-based classifiers achieved an area under the receiver operating characteristic curve (AUC) of greater than 0.8 for 14 types of cancer and and an AUC of greater than 0.9 for 2 types of cancer. CLCox models and CL-based classifiers trained with TCGA lung cancer and prostate cancer data were validated with the data of two independent cohorts.

We propose a novel formulation of the triplet objective function that improves metric learning without additional sample mining or overhead costs. Our approach aims to explicitly regularize the distance between the positive and negative samples in a triplet with respect to the anchor-negative distance. As an initial validation, we show that our method (called No Pairs Left Behind [NPLB]) improves upon the traditional and current state-of-the-art triplet objective formulations on standard benchmark datasets. To show the effectiveness and potentials of NPLB on real-world complex data, we evaluate our approach on a large-scale healthcare dataset (UK Biobank), demonstrating that the embeddings learned by our model significantly outperform all other current representations on tested downstream tasks. Additionally, we provide a new model-agnostic single-time health risk definition that, when used in tandem with the learned representations, achieves the most accurate prediction of subjects' future health complications. Our results indicate that NPLB is a simple, yet effective framework for improving existing deep metric learning models, showcasing the potential implications of metric learning in more complex applications, especially in the biological and healthcare domains. Metric learning is the task of encoding similarity-based embeddings where similar samples are mapped closer in space and dissimilar ones afar (Xing et al., 2002; Wang et al., 2019; Roth et al., 2020). Deep metric learning (DML) has shown success in many domains, including computer vision (Hermans et al., 2017; Vinyals et al., 2016; Wang et al., 2018b) and natural language processing (Reimers & Gurevych, 2019; Mueller & Thyagarajan, 2016; Benajiba et al., 2019). Many DML models utilize paired samples to learn useful embeddings based on distance comparisons. The most common architectures among these techniques are the Siamese (Bromley et al., 1993) and triplet networks (Hoffer & Ailon, 2015). The main components of these models are the: (1) Strategies for constructing training tuples and (2) objectives that the model must minimize. Though many studies have focused on improving sampling strategies (Wu et al., 2017; Ge, 2018; Shrivastava et al., 2016; Kalantidis et al., 2020; Zhu et al., 2021), modifying the objective function has attracted less attention.

Prof. Newton Howard, a Brain and Cognitive Scientist, the former Director of the MIT Mind Machine Project at the Massachusetts Institute of Technology and currently a Professor of Computational Neuroscience and Functional Neurosurgery at the University of Oxford, where he directs the Oxford Computational Neuroscience Laboratory participates in Risk Roundup to discuss "Mind Control Technology". Since the beginning of times, we humans have been creating tools to help us interact with the world around us. Now we are moving inwards and developing the tools to help us communicate with the world inside us. While the nature of tools has evolved from physical to digital, and now neural, our brain is effectively becoming the tool for interaction, communication, collaboration, and control. From electrode in many different shapes being implanted in the human brain to transmit and receive signals to non-invasive devices that translate brain waves into commands that control not only computer but also body parts are already becoming a reality.

Optimal performance is critical for decision-making tasks from medicine to autonomous driving, however common performance measures may be too general or too specific. For binary classifiers, diagnostic tests or prognosis at a timepoint, measures such as the area under the receiver operating characteristic curve, or the area under the precision recall curve, are too general because they include unrealistic decision thresholds. On the other hand, measures such as accuracy, sensitivity or the F1 score are measures at a single threshold that reflect an individual single probability or predicted risk, rather than a range of individuals or risk. We propose a method in between, deep ROC analysis, that examines groups of probabilities or predicted risks for more insightful analysis. We translate esoteric measures into familiar terms: AUC and the normalized concordant partial AUC are balanced average accuracy (a new finding); the normalized partial AUC is average sensitivity; and the normalized horizontal partial AUC is average specificity. Along with post-test measures, we provide a method that can improve model selection in some cases and provide interpretation and assurance for patients in each risk group. We demonstrate deep ROC analysis in two case studies and provide a toolkit in Python.